Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | 0.00% | -12.73% | -58.62% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Samuel Wickline
CTO | Chief Tech/Sci/R&D Officer | 71 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Margrit Schwarz
BRD | Director/Board Member | 60 | 21-07-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,240,245 | 2,220,245 ( 99.11 %) | 0 | 99.11 % |
Company contact information
Altamira Therapeutics Ltd.
Clarendon House 2 Church Street
HM 11, Hamilton
+441 295 5950
http://www.altamiratherapeutics.comSector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.57% | 111B | |
+11.57% | 105B | |
-12.87% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.02% | 16.96B | |
+3.54% | 13.7B | |
+37.74% | 12.45B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock
- Company Altamira Therapeutics